Kevin DeGeeter

Stock Analyst at Oppenheimer

(2.79)
# 1,747
Out of 4,853 analysts
43
Total ratings
33.33%
Success rate
52.16%
Average return

Stocks Rated by Kevin DeGeeter

AN2 Therapeutics
Apr 19, 2022
Initiates: Outperform
Price Target: $22
Current: $1.12
Upside: +1,864.29%
ORIC Pharmaceuticals
Mar 22, 2022
Downgrades: Perform
Price Target: n/a
Current: $9.16
Upside: -
Personalis
Feb 25, 2022
Maintains: Outperform
Price Target: $30$24
Current: $5.06
Upside: +374.31%
NovoCure
Feb 2, 2022
Upgrades: Outperform
Price Target: $98
Current: $16.45
Upside: +495.74%
Fulgent Genetics
Jan 25, 2022
Maintains: Outperform
Price Target: $141$125
Current: $20.82
Upside: +500.38%
MDxHealth
Nov 29, 2021
Initiates: Outperform
Price Target: $18
Current: $2.08
Upside: +767.47%
Sera Prognostics
Nov 19, 2021
Initiates: Outperform
Price Target: $19
Current: $1.60
Upside: +1,091.22%
Spero Therapeutics
Oct 1, 2021
Downgrades: Perform
Price Target: n/a
Current: $2.56
Upside: -
Portage Biotech
Sep 21, 2021
Initiates: Outperform
Price Target: $600
Current: $8.50
Upside: +6,958.82%
Palo Alto Networks
Aug 24, 2021
Maintains: Outperform
Price Target: $75$79
Current: $197.11
Upside: -59.83%
Maintains: Outperform
Price Target: $161$155
Current: $54.38
Upside: +185.03%
Downgrades: Perform
Price Target: n/a
Current: $0.36
Upside: -
Initiates: Outperform
Price Target: $25
Current: $4.31
Upside: +480.05%
Initiates: Outperform
Price Target: $4,080
Current: $0.61
Upside: +674,280.17%
Initiates: Outperform
Price Target: $1,800
Current: $2.58
Upside: +69,667.44%
Downgrades: Perform
Price Target: n/a
Current: $43.43
Upside: -
Initiates: Outperform
Price Target: n/a
Current: $2.88
Upside: -
Downgrades: Perform
Price Target: n/a
Current: $2.77
Upside: -
Initiates: Outperform
Price Target: $50
Current: $0.41
Upside: +12,151.90%
Initiates: Outperform
Price Target: $900
Current: $3.68
Upside: +24,356.52%
Upgrades: Buy
Price Target: n/a
Current: $6.99
Upside: -
Initiates: Buy
Price Target: $225
Current: $24.00
Upside: +837.70%
Upgrades: Neutral
Price Target: n/a
Current: $4.92
Upside: -
Upgrades: Buy
Price Target: n/a
Current: $2.26
Upside: -